A study suggested thatGLP-1receptor (GLP-1R) localization exists in C cells of rodents and the activation ofGLP-1R byGLP-1RA may promote C-cell proliferation andtumorformation, but for humans, a causal relationship betweenGLP-1RA and thyroid C-cell pathology has not been demonstrated (Bjerre Knudsen et al., 2010; Gier et al., 2012a).
The dramatic spike in glucagon-like peptide-1 (GLP-1) receptor agonist use is increasingly relevant to oncologists for various reasons, including a possible reduction in cancer risk and a potential role in survivorship care. "I haven't prescribed [GLP-1s],andI would say the majority of my colleagues would agree that they are not prescribing these drugs, but I do see a lot of patients on ...
As we can see from the illustration, Glp 1 And Autophagy In Tumor Studies has many fascinating aspects to explore.
A rapidly increasing proportion of the population in the United States is taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) for type 2 diabetes or weight loss. Consequently, an increasing number of patients presenting with new cases of cancer also have a current prescription forGLP-1RAs. The impact ofGLP-1RAs on metabolism is quite profound, and it is entirely reasonable to assume ...
Such details provide a deeper understanding and appreciation for Glp 1 And Autophagy In Tumor Studies.
The retrospective cohort study evaluated howGLP-1drugs affected incidence of 13 obesity-associated cancers, as well as lung cancer, among more than 86 600 adults with obesity or overweight with or without diabetes who had no previous cancer history. Patients opting forGLP-1medication had a lower overall cancer risk than untreated patients, with incidence rates of 13.6 vs 16.4 per 1000 ...
